Tags : Low-Dose Yervoy (ipilimumab)

Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose

Vartika Singh November 16, 2018

Shots: CHMP recommendation is based on the results of P-III CheckMate-214 study assessing Opdivo 3 mg/kg (q3w @four doses, q2w) + Yervoy 1 mg/kg vs sunitinib (50 mg qd @four […]readmore

Tags : Low-Dose Yervoy (ipilimumab)

Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Low-Dose Yervoy (ipilimumab)

Bristol-Myers Squibb Receives CHMP Recommendation for Opdivo (nivolumab) + Low-Dose

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company